PROCEPT BioRobotics Corporation Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
PROCEPT BioRobotics Corporation (PRCT) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2025-02-27
- PROCEPT BioRobotics Corporation right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- PROCEPT BioRobotics Corporation right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $186.00K.
- PROCEPT BioRobotics Corporation right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-12-31 was $0.00.
- PROCEPT BioRobotics Corporation right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00.
- PROCEPT BioRobotics Corporation right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- PROCEPT BioRobotics Corporation right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $22.85M.
- PROCEPT BioRobotics Corporation right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $0.00.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-27 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 10-K · filed 2025-02-27 | |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-02 | ||
| 2022-12-31 | $186.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $22.85M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $22.67M 10-Q · filed 2023-11-02 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $0.00 10-K · filed 2024-02-28 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |